Dr. Weinblatt has received consultant fees (less than $10,000 each) from Amgen, Pfizer, Abbott, Roche, Bristol-Myers Squibb, UCB, Centocor, and Wyeth.
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis†
Version of Record online: 25 FEB 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis Care & Research
Volume 63, Issue 3, pages 373–382, March 2011
How to Cite
Weinblatt, M. E., Bathon, J. M., Kremer, J. M., Fleischmann, R. M., Schiff, M. H., Martin, R. W., Baumgartner, S. W., Park, G. S., Mancini, E. L. and Genovese, M. C. (2011), Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res, 63: 373–382. doi: 10.1002/acr.20372
ClinicalTrials.gov identifiers: NCT00356590 and NCT00357903.
- Issue online: 25 FEB 2011
- Version of Record online: 25 FEB 2011
- Accepted manuscript online: 18 OCT 2010 01:09PM EST
- Manuscript Accepted: 4 OCT 2010
- Manuscript Received: 26 MAR 2010
- Immunex, Inc., a wholly owned subsidiary of Amgen, Inc.
- Wyeth, which was acquired by Pfizer, Inc., in October 2009
Additional Supporting Information may be found in the online version of this article.
|ACR_20372_sm_appendixa.doc||64K||SUPPLEMENTARY APPENDIX A: DISPOSITION OF PATIENTS IN ERA STUDIES|
|ACR_20372_sm_appendixb.doc||41K||SUPPLEMENTARY APPENDIX B: DISPOSITION OF PATIENTS IN LRA STUDIES|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.